Background {#Sec1}
==========

Primary Sjogren syndrome (pSS) is a chronic autoimmune epithelialitis targeting exocrine glands, with possible multisystem involvement \[[@CR1]\]. Characteristic pathological changes are focal lymphocytic infiltration around the epithelial ducts and production of autoantibody by hyperactive B cells \[[@CR2]\]. Renal involvement is observed in pSS, with both tubular and glomerular abnormalities reported. Tubulointerstitial nephritis (TIN) as a result of periepithelial inflammation is a predominant feature of pSS, often with evidence of a distal renal tubule acidosis (RTA) \[[@CR3]--[@CR5]\]. Fanconi syndrome, the result of proximal tubule epithelial cell (PTEC) injury leading to proximal RTA (type II RTA), hypophosphatemia, hypouricemia, aminoaciduria, glycosuria and urine loss of low molecular weight proteins, is a rare manifestation of pSS. To date, fewer than 20 cases have been reported and the underlying pathogenesis or mechanism remains unclear \[[@CR6]\].

Ectopic germinal centers (EGCs), nonlymphoid collections of mature B lymphocytes, have been observed in the labial glands of pSS patients, believed to be the result of chronic inflammation \[[@CR7]\]. The presence of CD21^+^ follicular dendritic cells is one of the hallmarks of EGCs \[[@CR8], [@CR9]\]. EGCs are suggested to be the site of immune stimulation and have been identified in other autoimmune diseases, such as rheumatoid arthritis and Grave's disease. Self-reactive T lymphocytes and antibodies contribute to the process of tissue destruction and disease progression \[[@CR10]\]. Recent studies suggest that Th17 cells, a subset of CD4^+^ T cells, may directly contribute to lymphoneogenesis in labial glands of pSS patients \[[@CR11]\], but it is unclear whether a similar process occurs in the kidney of pSS patients with Fanconi syndrome. Inhibition of receptor-mediated endocytosis has been proposed as the mechanism of Fanconi syndrome in other disease states. Megalin and cubilin are multiligand protein receptors expressed at the brush border membrane and involved in endocytosis in PTECs. Megalin-knockout mice and cubilin-deficient dogs demonstrate deficient endocytosis, reproducing low-molecular proteinuria and vitamin D deficiency, which are the main characteristics of human Fanconi syndrome \[[@CR12], [@CR13]\].

In this study, we report the clinical and pathological characteristics and therapeutic outcomes of 12 patients with pSS and Fanconi syndrome. We describe the presence of EGCs in the renal interstitium, the prevalence of Th17/IL-17 expression, and alterations in megalin and cubilin expression, to investigate their possible correlation.

Methods {#Sec2}
=======

Patients and controls {#Sec3}
---------------------

All patients diagnosed with primary Sjogren syndrome with renal Fanconi syndrome in Peking Union Medical College Hospital (PUMCH) from 1994 to 2014 were enrolled. The diagnosis of pSS was made according to the American--European Consensus Group criteria for pSS \[[@CR14]\]. Fanconi syndrome was defined by the coexistence of hypokalemia, hypophosphatemia, normoglycemic glycosuria, generalized aminoaciduria and hyperphosphaturia \[[@CR15]\]. Clinical records and follow-up data of enrolled patients were carefully reviewed to understand demographic characteristics, symptoms, physical examination and laboratory tests. Laboratory examinations included routine tests: blood, urine, liver and renal function, 24-h urine protein, erythrocyte sedimentation rate (ESR), C-reactive protein and plasma protein electrophoresis. Renal tubular function assay included: blood and urine electrolytes, blood and urine α~1~-microglobulin (α~1~-MG), β~2~-microglobulin (β~2~-MG), blood pH, carbon dioxide combining power, urine *N*-acetyl-β-amino-glucosidase (NAG), retinol binding protein (RBP) and blood and urine osmotic pressure tests. Immunology assay included: immunoglobulin (IgG, IgA, IgM), rheumatoid factor (RF), blood complement and antinuclear antibodies spectrum. Screening for autoantibodies to SSA/Ro and SSB/La was performed systematically using Ouchterlony double-gel immunodiffusion and western blotting. Other tests included lacrimal and salivary gland secretion test (Schirmer test), salivary scintigraphy, parotid sialography and labial biopsy. The estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease (MDRD) study equation \[[@CR16]\]. Systemic manifestations of these patients were evaluated by Eular Sjogren's Syndrome Disease Activity Index (ESSDAI) \[[@CR17]\]. Twenty patients with pSS and tubulointerstitial nephritis (pSS + TIN) were included as the control group. TIN clinically manifested as hematuria, leucocyturia, proteinuria (24-h urine protein \< 2 g), renal function impairment, distal RTA and hypokalemia, with mainly tubulointerstial impairment in renal biopsies, with or without minor glomerular damage. They had the same workup to exclude proximal tubule injury. Six cases of glomerular minor lesion (GML) were selected as normal controls. These normal patients underwent renal biopsy in the setting of mild isolated hematuria and strong desire for renal biopsy to figure out the etiology, but were not found to have underlying pathology.

Pathologic studies of kidney tissue {#Sec4}
-----------------------------------

Two-micrometer slides were cut from formalin-fixed and paraffin-embedded (FFPE) sections of kidney tissues, stained with hematoxylin and eosin, periodic acid--Schiff, periodic acid--silver metheramine and Masson trichrome for light microscopy in the laboratory of Nephrology Department at PUMCH. At least eight sections were examined for each patient. All sections were examined by an experienced pathologist who was blinded to the patient's characteristics. Tubulointerstitial injury was evaluated based on the Oxford Classification of IgA glomerulonephritis \[[@CR18]\]. The classification used to describe the degree of lymphocytic infiltration in renal tissue was similar to that used in previous studies of the labial gland in patients with Sjogren syndrome: grade 0 (G0), absent, no lymphocyte infiltration; grade 1 (G1), slight infiltration, scattered lymphocytes infiltrating with an aggregate of fewer than 50 cells; grade 2 (G2), moderate infiltration, focal periductal lymphocytes aggregating in the labial gland, with 50 or more cells per one lesion; and grade 3 (G3), dense infiltration showing EGC-like structures in labial gland and CD21 staining positive \[[@CR19]\].

Immunohistochemistry staining of megalin, cubulin, CD21 and IL-17A {#Sec5}
------------------------------------------------------------------

Immunohistochemical (IHC) staining was performed on serial sections using standard methods in five pSS patients with Fanconi syndrome who underwent renal biopsy, five pSS + TIN patients (randomly selected from 20 patients in the control group) and six GML patients. Three-micrometer sections cut from paraffin-embedded tissue were deparaffinized and rehydrated. Sections were heated in a pressure cooker with 0.01 mol/L citrate buffer (pH 6.0) for 5 min to expose antigen and then incubated with the primary antibody (megalin, IL-17A and CD21, rabbit polyclonal antibodies; Abcam, Cambridge, MA, USA; cubilin, goat polyclonal antibody; Santa Cruz, CA, USA) overnight at 4 °C. After incubation with 0.3% H~2~O~2~ for 15 min, sections were incubated with the 1:500 HRP-conjugated anti-rabbit or anti-goat IgG (ImmunoReagents, USA) for 1 h at 37 °C. 3,3′-Diaminobenzidine (DAB) was used as a staining substrate. All section images were captured by a Nikon microscope (Eclipse 80i; Nikon, Japan) equipped with a digital photograph camera (DS-U1; Nikon, Japan).

Megalin immunofluorescence staining was done on 3-μm paraffin sections. The slides were incubated with primary antibody (megalin, rabbit polyclonal antibody; Abcam) overnight at 4 °C. Secondary antibody fluorescein-conjugated AffiniPure donkey anti-rabbit IgG (EarthOx, USA) was applied and incubated at 37 °C for 1 h. The micrographs were taken by confocal laser microscopy (Leica, Germany).

The degree of IHC staining was evaluated by calculating the percentage of positive glomeruli. Staining and scoring were performed blindly on coded slides. At least six fields were selected randomly in the renal cortex of each specimen for photo-documentation. Analytical measurements were done using Image Pro Plus 6.0.

Statistical analysis {#Sec6}
--------------------

Continuous variables are presented as the mean ± standard deviation. The variables consistent with normal distribution were compared using Student's *t* test, one-way analysis of variance or Pearson's correlation coefficients; skewed distribution samples were compared using the Mann--Whitney test or Spearman's correlation. Categorical variables are expressed as percentages and are compared using the chi-square test. Statistical processing was performed using Graphpad Prism 6.0 and *p* \<0.05 was considered statistically significant.

Results {#Sec7}
=======

Clinical characteristics {#Sec8}
------------------------

From January 1994 to August 2014, 2546 hospitalized patients in PUMCH were diagnosed of pSS, 335 of them presenting with renal manifestation (different degree of haematuria, proteinuria, tubule acidosis or renal function defect). By screening the medical records, 12 (0.47%) pSS patients with Fanconi syndrome were identified, five of whom underwent renal biopsy due to renal function impairment (eGFR compared with those without renal biopsy: 30.0 ± 8.5 vs 98.1 ± 27.5, *p* \< 0.001). They were predominantly female, with a mean age of 39.3 ± 8.6 years. The male:female ratio was 1:5. At the onset, six patients presented with fatigue or anoxia, two developed hypokalemia paralysis, one developed bone pain and one had proteinuria. Two patients had sicca syndrome as the chief complaint initially. Systemic manifestations evaluated by ESSDAI ranged from 7 to 27, with an average of 18.8 ± 7.8. Weight loss (58.3%) was the most prominent symptom. Anemia (58.3%, hemoglobin averaged 105.3 ± 25.3 g/L), glandular involvement (16.7%), cutaneous lesion (8.3%) and pulmonary involvement (8.3%) were also observed. ANA was elevated in 75% of patients, and anti-Ro/SSA or anti-La/SSB antibodies were detected in eight (42.7%) and three (25.0%) patients, respectively. Eight of 11 (72.7%) patients showed increased immunoglobulin level. Two of 12 (16.7%) patients had increased RF level, and 3/12 (25%) patients showed decreased blood complement level. Laboratory studies consistent with proximal tubular injury were common with hypokalemia (100%), hypophosphatemia (83.3%), glycosuria (83.3%), RTA (75.0%) and aminoaciduria (72.7%). It is noteworthy that a majority of patients were associated with defects in other parts of the tubule, as proximal and distal RTA always coexistent. Eleven of 12 patients presented with albuminuria, ranging from trace to 1.0 g/L. Increased total protein in the urine was elevated in 10 patients, averaging 1.8 ± 0.5 g/24 h. Average eGFR was 69.8 ± 40.9 ml/min/1.73 m^2^, with five patients (41.7%) under 60 ml/min/1.73 m^2^. Table [1](#Tab1){ref-type="table"} compares the clinical profile between pSS patients with Fanconi syndrome and those with tubulointerstitial nephritis (pSS + TIN) who did not present with proximal tubule dysfunction. The pSS + Fanconi group had lower serum phosphorus level and more prominent proteinuria. Systemic manifestations showed no significant difference.Table 1Comparison of clinical profile between patients with pSS + Fanconi syndrome and pSS + TINpSS with Fanconi syndromepSS with TIN*P* value\*(*N* = 12)(*N* = 20)Age (years)39.3 ± 8.637.6 ± 12.20.366Gender (female %)10 (83.3)18 (90.0)0.620Presenting symptoms Polyuria8 (66.7)10 (50.0)0.471 Muscle weakness9 (75.0)14 (70.0)1.000 Nocturia7 (58.3)5 (25.0)0.130 dRTA9 (75.0)11 (55.0)0.452 Paralysis3 (25.0)6 (30.0)1.000 SCr elevation9 (75.0)12 (60.0)0.465 eGFR (ml/min/1.73 m^2^)66.08 ± 38.2076.14 ± 39.570.716 Serum potassium (mmol/L)2.79 ± 0.142.76 ± 0.240.120 Serum calcium (mmol/L)2.23 ± 0.142.13 ± 0.090.104 Serum phosphorus (mmol/L)0.69 ± 0.331.02 ± 0.290.001 24-h urine protein (g/24 h)1.51 ± 0.841.00 ± 0.610.019Systemic manifestations ESSDAI18.83 ± 7.8315.50 ± 6.530.289 Weight loss (\>5%)7 (58.3)6 (30.0)0.150 Glandular2 (16.7)3 (15.0)1.000 Cutaneous1 (8.3)1 (5.0)1.000 Pulmonary1 (8.3)3 (15.0)1.000 Lymphadenopathy0 (0.0)2 (10.0)0.516 HGB (g/L)105.3 ± 25.2113.4 ± 13.60.408Immune profile ESR (mm/h)58.8 ± 30.942.7 ± 30.90.141 ANA positive9 (75.0)18 (90.0)0.338 SSA positive5 (41.7)14 (73.7)0.130 SSB positive3 (25.0)19 (47.1)0.273 IgG (g/L)18.3 ± 8.219.7 ± 6.30.588Data presented as number (%) or mean ± SD unless otherwise noted*ANA* antinuclear antibody, *dRTA* distal renal tubule acidosis, *eGFR* estimated glomerular filtration rate, *ESR* erythrocyte sedimentation rate, *ESSDAI* Eular Sjogren's Syndrome Disease Activity Index, *HGB* hemoglobin, *IgG* immunoglobulin G, *pSS* primary Sjogren syndrome, *SCr* serum creatinine, *SSA* Sjogren-syndrome-related antigen A, *SSB* Sjogren-syndrome-related antigen B, *TIN* tubulointerstitial nephritis\*Mann--Whitney (two-tailed) test for continuous variables and Fisher's exact (two-tailed) test for categorical variables

Histopathological features {#Sec9}
--------------------------

The biopsies of five pSS patients with Fanconi syndrome who underwent renal biopsy were reviewed. The primary lesion was moderate TIN with minimal glomerular injury and notable proximal tubular injury. Changes included tubule atrophy with defective brush border (64.0 ± 12.1%) and interstitial fibrosis (58.0 ± 12.8%) (Fig. [1a](#Fig1){ref-type="fig"}, [b](#Fig1){ref-type="fig"}). Renal biopsy of Patient 3 revealed acute interstitial nephritis (AIN) with lymphocytic infiltration. Dense lymphocytes, monocytes, eosinophils and plasma cells could be identified in the focal lesion (Fig. [1c](#Fig1){ref-type="fig"}, [d](#Fig1){ref-type="fig"}).Fig. 1Patients with pSS + Fanconi syndrome show remarkable pathological lesions of renal proximal tubule. **a** Masson staining reveals interstitial fibrosis. **b** Boxed area in **a** enlarged. **c** Hematoxylin and eosin E staining indicating focus of lymphocyte infiltration. **d** Boxed area in **c** enlarged, indicating plasma cells in lymphocytes focus

Megalin and cubilin expression {#Sec10}
------------------------------

Compared with normal controls (GML), the expression of megalin and cubilin on proximal tubule cells was decreased (Fig. [2](#Fig2){ref-type="fig"}). As shown in semiquantitative analyses, the positive area staining ratio of megalin and cubilin in pSS patients with Fanconi syndrome was significantly lower than that in the control GML group (Fig. [2D](#Fig2){ref-type="fig"}, [E](#Fig2){ref-type="fig"}) (0.10 ± 0.01 vs 0.16 ± 0.02, *p* = 0.030; 0.05 ± 0.01 vs 0.11 ± 0.01, *p* = 0.004, respectively). Megalin and cubilin expression showed no significant difference between pSS + TIN patients and the GML group (0.14 ± 0.01 vs 0.16 ± 0.01, *p* = 0.320; 0.10 ± 0.01 vs 0.11 ± 0.01, *p* = 0.628), while there was a trend toward reduced expression in SS + Fanconi syndrome patients compared with the pSS + TIN group (0.10 ± 0.02 vs 0.14 ± 0.01, *p* = 0.095; 0.05 ± 0.01 vs 0.10 ± 0.01, *p* = 0.008).Fig. 2Immunohistochemistry and immunofluorescence reveals loss of megalin and cubilin expression in pSS patients with Fanconi syndrome. Staining of megalin (**A**, **C**) and cubilin (**B**) on kidney biopsies of patients with glomerular minor lesion (GML) (*Aa*, *Ba*, *Ca*), patients of pSS with tubulointerstitial nephritis (*Ab*, *Bb*), and pSS patients with Fanconi syndrome (*Ac*, *Bc*, *Cb*). Semiquantitative analysis shows decreased expression of megalin (**D**) and cubilin (**E**) in pSS patients with Fanconi syndrome, compared with GML and SS + TIN groups. *GML* glomerular minor lesion, *SS* Sjogren syndrome, *TIN* tubulointerstitial nephritis

Presence of CD21^+^ germinal centers {#Sec11}
------------------------------------

Focuses of lymphocytic infiltration could be seen in all biopsies of patients with pSS and Fanconi syndrome. There were three of G1, two of G2 and one of G3. The dendritic cell marker CD21^+^ was observed in one patient who showed the characteristics of AIN. There were several CD21^+^ focuses, indicating the presence of EGCs scattered in the renal interstitium (Fig. [3](#Fig3){ref-type="fig"}). We observed that the patient with G3 lymphocyte focus showed the lowest megalin and cubilin positive staining ratio. No specific relationship was identified between focus grading and expression levels of megalin or cubilin due to the small sample size.Fig. 3EGC of pSS with Fanconi syndrome. Immunohistochemical staining for CD21 in the kidney cortex (**a**, **b**) (boxed area in **a** is enlarged in **b**: **a** × 40, **b** × 200). Classification of lymphocytes aggregating in the proximal tubule: **c** G1, **d** G2 and **e** G3

Expression of IL-17A and megalin in serial sections {#Sec12}
---------------------------------------------------

Diffuse expression of IL-17, a proinflammatory cytokine contributing to the formation of germinal centers, was observed in proximal renal tubules with variable intensity, while none was observed in the glomerulus. Both cytoplasm and cell membranes of the proximal renal tubule stained positively. It was noticeable that in the adjacent kidney paraffin sections of Patient 3, proximal tubules with strong IL-17A staining lacked expression of megalin, and vice versa (Fig. [4a](#Fig4){ref-type="fig"}, [b](#Fig4){ref-type="fig"}). Infiltrating cells expressing IL-17A were identified in renal interstitium after hematoxylin staining of nucleus (Fig. [4c](#Fig4){ref-type="fig"}, [d](#Fig4){ref-type="fig"}).Fig. 4Expression of IL-17A and megalin in serial sections. Immunohistochemical staining of IL-17A (**a**) and megalin (**b**) on adjacent kidney paraffin sections from a patient with pSS + Fanconi syndrome. Proximal tubules with high expression of IL-17A show loss of megalin (*asterisks*), and those with preserved megalin expression have no IL-17A staining (*arrow*). **c**, **d** Identification of IL-17A expressing cells (*arrow*) in renal interstitium with hematoxylin staining of nucleus

Treatment and follow-up {#Sec13}
-----------------------

All patients received treatment primarily with glucocorticosteroids with an initial dose of prednisone typically 0.5--1 mg/kg/day. Three patients also received cyclophosphamide or methotrexate in addition to prednisone. Patients generally showed good response to treatment, with a significant increase of eGFR (26--235%) over the median in-hospital time of 3 weeks. Five patients with impaired renal function were followed for an average of 59 months (1--192 months). During the follow-up, all patients showed improved renal function, with SCr decreased 39.2% on average. Their renal function remained stable with no flares (SCr higher than at onset, with/or 24-h UP \> 0.3 g) and no requirement for renal replacement therapy. Electrolyte derangement also corrected with treatment, allowing a reduction in oral supplementation.

Discussion {#Sec14}
==========

The most common renal manifestation of pSS is a distal RTA, with proximal tubular acidosis seldom reported \[[@CR20]\]. Fanconi syndrome, general dysfunction of the proximal tubule, is a relatively rare clinical manifestation of pSS. By searching PubMed with ((Sjogren syndrome) or (autoimmune epithelialitis)) and ((renal tubule) OR Fanconi), about 20 cases were identified \[[@CR6], [@CR21]--[@CR35]\]. Wang et al. \[[@CR6]\] and Shi and Chen \[[@CR33]\] have summarized SS-related Fanconi syndrome cases that had been reported. We made a supplement to their summarization. We reported 12 cases of pSS + Fanconi syndrome cases with detailed clinical profile and follow-up records, to our limited knowledge, which is the largest sample in a single center. As presented in Table [2](#Tab2){ref-type="table"}, similar clinical and pathological characteristics were observed in our study. In our series, 58% patients had impaired renal function with moderate TIN, and showed good response to glucocorticoid therapy. Both tubular function injury and eGFR were improved following treatment with steroids.Table 2Comparison of clinical profile between our cases and pSS-related Fanconi syndrome reported in the literatureReferencePresenting symptomsRTACrK (mmol/L)HistologyTreatmentOutcomeShearn and Tu \[[@CR29]\]Polyuria+n.a.3.8TIN, tubular atrophyn.a.n.a.Walker et al. \[[@CR30]\]Paralysis, polyuria+n.a.n.a.TINPrednisolone 10 mg/dayn.a.Kamm and Fischer \[[@CR24]\]Polyuria, nocturia, weight loss+2.7 mg/dl2.9Diffuse TINSupportive onlyImprovedMatsumura et al. \[[@CR26]\]n.a.n.a.2.7 mg/dln.a.TIN, tubulitisn.a.n.a.Ardiles et al. \[[@CR21]\]Muscle weakness+1.3 mg/dl2.5n.a.Prednisolone "low dose"ImprovedBridoux et al. \[[@CR22]\]Weight loss+1.8 mg/dl3.5Diffuse TIN, proximal tubulitisSupportive onlyDied^a^Polyuria+1.6 mg/dl2.4Diffuse TIN, proximal tubulitisPrednisolone 10 mg/dayImprovedKobayashi et al. \[[@CR25]\]Muscle weakness+1.3 mg/dl2.7Diffuse TIN, proximal tubule atrophyPrednisolone 30 mg/day, 6 months later 12.5 mg/dayImprovedRen et al. \[[@CR32]\]^b^n.a.Yang et al. \[[@CR31]\]Muscle weakness, respiratory distress+1.4 mg/dl2.7n.a.Supportive onlyn.a.Nakamura et al. \[[@CR27]\]Renal dysfunction, organizing pneumonia, multiple bone fracture+1.3 mg/dl3.0n.a.Mizoribine 50 mg/dayn.a.Wang et al. \[[@CR6]\]Hypokalemic paralysis+2.2 mg/dl1.6Diffuse TINMycophenolate mofetil 1 g/dayImproved^f^Ram et al. \[[@CR28]\]Paralysis+2.1 mg/dl1.3Dense lymphocytic interstitial infiltrateSupportive onlyImprovedCelik et al. \[[@CR23]\]Paralysis, cardiac arrest^c^+1.1 mg/dl1.1n.a.Prednisone 40 mg/d iv. in acute phaseImproved^f^Shi and Chen \[[@CR33]\]Proteinuria, glycosuria^d^+3.07TINMethylprednisoloneImproved^e^Saeki et al. \[[@CR34]\]Renal dysfunction+1.07 mg/dl3.7TINPrednisolone 40 mg/dayImproved^e^Kong et al. \[[@CR35]\]Weakness, osteodynia, impaired mobility_n.a.1.3n.a.Prednisone 30 mg/dayOur casesFatigue, anorexia+151 μmol/L3.4Diffuse TIN, diffuse tubule atrophy, lymphocyte infiltrationPrednisone 50 mg/dayImproved^f^Fatigue, polyuria, anorexia, osteopathy+88 μmol/L2.1Focal TIN, focal tubule atrophyPrednisone 40 mg/dayImproved^f^Fatigue, anorexia, osteopathy+176 μmol/L3.3Diffuse TIN, diffuse tubule atrophy, lymphocyte infiltrationPrednisone 50 mg/dayImproved^e^Fatigue, anorexia+305 μmol/L2.7Focal TIN, focal tubule atrophyPrednisone 45 mg/dayImproved^e^Fatigue, anorexia, polyuria--72 μmol/L2.53Mild tubulitisSupportive onlyImproved^f^Fatigue, anorexia, polyuria+184 μmol/L3.0n.a.Prednisone 35 mg + cyclophosphamide 0.2 g qodImproved^e^Polyuria--120 μmol/L3.4n.a.Prednisone 60 mg/dayImproved^e^Fatigue, polyuria, anorexia, osteopathy+202 μmol/L2.62n.a.Prednisone 55 mg/dayImproved^e^Osteopathy--110 μmol/L3.2n.a.Prednisone 55 mg/day + metrotraxate 10 mg qwImproved^f^Fatigue, polyuria, osteopathy+75 μmol/L2.88n.a.Prednisone 40 mg/day + cyclophosphamide 0.2 g qodImproved^f^Hypokalemic paralysis, osteopathy+65 μmol/L2.1n.a.SupportiveImproved^f^polyuria, osteopathy+71 μmol/L2.34n.a.Prednisone 30 mg/day + metrotraxate 10 mg qwImproved^f^Mean age of patients with pSS-related Fanconi syndrome reported in the literature is 47.4 ± 13.2, with a female ratio of 93.3%*n.a.* not available, *pSS* primary Sjogren syndrome, *qop* every other day, *qw* every week, *RTA* renal tubule acidosis, *TIN* tubulointerstitial nephritis^a^Probable cardiovascular event^b^Four cases reported in a retrospective study of 130 cases, no detailed information^c^Also diagnosed of brucellic disease^d^With autoimmune thyroiditis^e^Improvement of renal function, and stable during follow-up^f^Correction of electrolyte derangement, and relief of symptoms

Few studies have focused on the mechanism of Fanconi syndrome or PTEC injury in pSS. We observed the downregulation of megalin and cubilin in PTECs, which suggests defective endocytosis. Megalin and cubilin are endocytic receptors coexpressed in the proximal tubule, located on the brush border and endocytic vesicles. They bind and mediate the endocytosis of a variety of ligands, including enzymes or enzyme inhibitors, lipoproteins, hormones, signaling proteins, immune or stress response-related proteins, receptors and vitamin carrier proteins as well as drugs and toxins \[[@CR12], [@CR36]\]. Megalin and cubilin are associated with key processes to fulfill the classic reabsorption function of proximal tubules: the integrity of cell structure, such as polarity, brush border and endocytic apparatus; apical multiligand receptors megalin and cubilin; and intact transport system consisting of microvilli, clathrin-coated pits, early endosomes, late endosomes and lysosome. The other processes include energy production by mitochondria and basolateral Na^+^-K^+^-ATPase as the driving force for Na^+^-coupled transport \[[@CR13], [@CR37]--[@CR39]\]. In cystinosis, a known cause of Fanconi syndrome, alterations in megalin activity have been noted on the brush border, endosomes and lysosomes by immunofluorescence under electron microscopy \[[@CR40]\]. Megalin and cubilin have also been shown to be critical in Fanconi syndrome from other causes. Mutations in the gene low-density lipoprotein receptor-related protein 2 (*LRP2*), encoding the protein megalin, have been identified in Donnai-Barrow (DB) syndrome and Facio-Oculo-Acustico-Renal (FOAR) syndrome. These patients show prominent low-molecular weight proteinuria, with malabsorption of vitamin D-binding protein, retinol-binding protein and albumin \[[@CR41]\]. Elegant experiments have suggested urinary megalin deficiency implicating abnormal tubular endocytic function in Fanconi syndrome related to Dent's disease and Lowes syndrome \[[@CR42]\]. In these genetic disorders, the down-expression of megalin/cubilin caused by impaired endosome--lysosome trafficking has also been shown \[[@CR43], [@CR44]\]. On the other hand, megalin-mediated endocytosis of excessive protein is pathogenic in light-chain tubulopathy. It has been shown that silencing megalin and cubilin genes may inhibit myeloma light chain uptake, suppressing inflammation in PTECs, and reducing the nephrotoxic effects \[[@CR45]\]. The mechanism of drug-induced Fanconi syndrome is not fully understood at this point in time \[[@CR46]\]. However, as far as we can see, the mechanism of Fanconi syndrome caused by pSS has not yet been discussed. The innovation of our study is to show that defect endocytosis in PTECs mediated by megalin and cubilin may contribute to the reabsorption impairment in patients with pSS and Fanconi syndrome. A trend toward loss of megalin expression was observed in pSS with TIN, but this was not significant compared with the decreased expression of megalin noted in patients with pSS and Fanconi syndrome. We propose that proximal tubule impairment was less severe in TIN with general tubule injury, because no symptoms of endocytic receptor defect were observed.

The mechanism of megalin and cubilin alteration remains poorly understood, although past studies have indicated that renal ischemia and reperfusion injury, inflammation and drugs may all be causative. Lipopolysaccharide has been shown to downregulate megalin and cubulin expression in vitro and vivo \[[@CR47]\]. In this study, we first observed the inverse relationship of megalin and IL-17 expression with associated ectopic germinal center (EGC) formation in the kidney. IL-17 is a proinflammatory cytokine secreted by Th17 cells, which comprise a distinct subset of CD4^+^ T cells that play a role in autoimmune disease \[[@CR48]\]. Th17 cells are believed to activate follicular dendritic cells and stromal cells via surface molecule LTα1β2 and they secrete IL-17, stimulating stromal cells, fibroblasts and tissue epithelial cells to produce chemokines \[[@CR11]\]. IL-17 secretion is induced by IL-21, produced by Tfh cells, a component of EGCs. IL-17 then acts in conjunction with IFNγ to recruit lymphocytes for the formation of the germinal center \[[@CR49]\]. In addition, we observed that renal proximal tubule cells can express IL-17. It is reasonable to assume that epithelial cells may be an important component of immune response in TIN, as has been indicated in renal transplant rejection. EGCs are highly organized lymphoid aggregates that form in tissue sites which are not typically associated with lymphoid neogenesis \[[@CR50]\]. TIN is characterized by organized infiltration of anatomically distinct and adjacent T-cell and B-cell compartments, with the presence of follicular dendritic cells (DCs) \[[@CR9]\]. As the infiltrating cells, DCs have been shown to be necessary and sufficient in the formation of EGCs \[[@CR51]--[@CR53]\], Depletion of DCs leads to disappearance of existing follicular germinal center structure \[[@CR52]\]. We observed that circulating pDCs and mDCs were reduced in pSS patients with TIN, compared with patients with pSS alone. In addition, immunohistochemical staining of BDCA-2 and DC-SIGN revealed increased pDCs and mDCs in renal interstitium. Combining these findings, we assume that in the setting of local inflammation in pSS, DCs can be recruited to renal tissue from peripheral blood (unpublished data). CD21 remains the most reliable marker of follicular dendritic cells. In another study of our group, we find that in pSS with membranous nephrology, all G3 patients (30.5% of 36 patients) showed positive CD21 staining with varying degree, and typical EGC structure was seen in nine patients. The relationship of IL-17 and germinal center activity has been observed previously. In an experimental autoimmune encephalomyelitis murine model, Th17 cells also directly elicit formation of ectopic lymphoid follicle formation, by surface molecule podoplanin and secretion of IL-17 \[[@CR54]\]. In the formation of inducible bronchus associated lymphoid tissue (iBALT), IL-17 secreted by Th17 cells contributes to the initial stage \[[@CR55]\]. In the labial glands with pSS, germinal centers developed in 25.1 ± 5.0% of patients \[[@CR56]\]. Both Sakai et al. and Fei et al. reported that the majority infiltrating cells in the salivary glands of SS patients were CD4^+^ T cells, with a predominant expression of IL-17 \[[@CR56], [@CR57]\], which could be modified by immunosuppressive treatment \[[@CR57]\]. Consistent with their findings, we observed infiltrating cells expressing IL-17A present in renal interstitium (we did not perform CD4 and IL-17A double-staining to clarify Th17 cells due to limited pathological sections). There is also evidence to suggest that EGC formation may contribute to progression of disease in lupus nephritis \[[@CR58], [@CR59]\]. Therefore, the presence of DCs and EGCs in the interstitium of the kidney in patients with pSS suggests that the severe renal interstitial inflammation, with Th17 infiltration and IL-17 secretion, may be correlated to megalin and cubilin impairment. We suppose that local inflammation may subsequently mediate brush border destruction, characterized by decreased megalin and cubilin expression, leading to the reabsorptive dysfunction of PTECs and Fanconi syndrome.

There are several limitations of our study. First, not all patients underwent bicarbonate loading test, and patients with isolated proximal tubule acidosis could not be identified. Second, as a retrospective study, instead of the mechanism we only suggested a correlation between EGC formation and defected endocytosis characterized by megalin/cubilin down-expression. It is possible that megalin/cubilin deficiency is a reflection of generalized proximal tubule injury, because up to 45.2% of pSS patients were present with elevated excretion of β~2~-microglobulin. Third, a different degree of inflammation may not explain the whole picture of why only certain pSS + TIN patients present with proximal tubule defect. Whether this is due to specific local antibody remains to be elucidated by further study.

Conclusion {#Sec15}
==========

Collectively, we reported 12 cases of pSS with Fanconi syndrome. They present with proximal tubular defect, decreased eGFR and tubulointerstitial nephritis, and they show good response to glucocorticosteroids therapy. Down-expression of megalin and cubilin may cause the endocytosis reabsorption dysfunction of proximal renal tubules. We suggest that this is related to Th17 infiltration, IL-17 expression and formation of ectopic germinal centers.

ANA

:   Antinuclear antibody

DC

:   Dendritic cell

EGC

:   Ectopic germinal center

eGFR

:   Estimated glomerular filtration rate

ESR

:   Erythrocyte sedimentation rate

ESSDAI

:   Eular Sjogren's Syndrome Disease Activity Index

FFPE

:   Formalin-fixed and paraffin-embedded

GML

:   Glomerular minimal lesion

IL-17

:   Interleukin 17

MDRD

:   Modification of Diet in Renal Disease

NAG

:   *N*-acetyl-β-amino-glucosidase

pSS

:   Primary Sjogren syndrome

PTEC

:   Proximal tubule epithelial cell

RBP

:   Retinol binding protein

RTA

:   Renal tubule acidosis

SCr

:   Serum creatinine

SSA

:   Sjogren-syndrome-related antigen A

SSB

:   Sjogren-syndrome-related antigen B

TIN

:   Tubulointerstitial nephritis

α~1~-MG

:   α~1~-Microglobulin

β~2~-MG

:   β~2~-Microglobulin
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